Promentis Pharmaceuticals Overview

  • Founded
  • 2007
Founded
  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • Later Stage VC
  • Investors
  • 10

Promentis Pharmaceuticals General Information

Description

Developer of first-in-class therapies designed to treat central nervous system disorders. The company's therapies are focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders, enabling healthcare practitioners to treat various psychiatric disorders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Pharmaceuticals
Primary Office
  • 826 North Plankinton Avenue
  • Suite 400
  • Milwaukee, WI 53203
  • United States
+1 (414) 000-0000

Promentis Pharmaceuticals Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Promentis Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 01-Nov-2020 000.00 Completed Clinical Trials - Phase 2
9. Debt - General 10-Dec-2019 000.00 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series C) 04-Dec-2019 000 000.00 000.00 Completed Clinical Trials - Phase 2
7. Later Stage VC (Series C) 22-Sep-2017 000.00 000.00 000.00 Completed Pre-Clinical Trials
6. Grant 01-Jan-2015 00000 00.000 Completed Pre-Clinical Trials
5. Later Stage VC (Series B) 31-Dec-2013 00.000 00.000 000.00 Completed Pre-Clinical Trials
4. Grant 28-Sep-2012 00.00 00.000 Completed Startup
3. Early Stage VC (Series A) 25-Feb-2010 00.000 00.000 00.00 Completed Startup
2. Debt - General 11-Feb-2010 $250K Completed Startup
1. Grant 01-Jan-2008 $508K Completed Startup
To view Promentis Pharmaceuticals’s complete valuation and funding history, request access »

Promentis Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000,000 00.000000 00 00 00 00 00 00.000
Series B 0,000,000 00.000000 00 00 00 00 00 0.000
Series A 2,224,536 $0.001000 8% $0.88 $0.88 1x $0.88 5.13%
To view Promentis Pharmaceuticals’s complete cap table history, request access »

Promentis Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of first-in-class therapies designed to treat central nervous system disorders. The company's therapies are fo
Drug Discovery
Milwaukee, WI
6 As of 2021
000.00
0000000000 0 000.00

000000

nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
0000 00000000
Mountain View, CA
00 As of 0000
00000
000 0000-00-00
000000&0 00000

000000 0

re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur
0000 000000000
Aliso Viejo, CA
000 As of 0000
0000
0.00 0000-00-00
000000&0 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Promentis Pharmaceuticals Competitors (22)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alexza Formerly VC-backed Mountain View, CA 00 00000 000000&0 00000
000000 00000000000 Corporate Backed or Acquired Aliso Viejo, CA 000 0000 000000&0 0000
000000000 Formerly VC-backed Rehovot, Israel 00 000.00 000000&0 000.00
00000 000000000000 Venture Capital-Backed Redmond, WA 00 00000 00000000 00000
00000000 Private Equity-Backed Rye Brook, NY 00 000.00 0000000 0000 000.00
You’re viewing 5 of 22 competitors. Get the full list »

Promentis Pharmaceuticals Executive Team (8)

Name Title Board Seat Contact Info
Klaus Veitinger Ph.D Co-Chief Executive Officer & Chairman
Daniel Lawton Co-Founder, Co-Chief Executive Officer, President & Board Member
Michael Neary Director of Research
Chad Beyer Ph.D Senior Vice President, Research & Development
Stacy Holland Vice President of Finance
You’re viewing 5 of 8 executive team members. Get the full list »

Promentis Pharmaceuticals Board Members (12)

Name Representing Role Since
Daniel Lawton Promentis Pharmaceuticals Co-Founder, Co-Chief Executive Officer, President & Board Member 000 0000
Klaus Veitinger Ph.D Promentis Pharmaceuticals Co-Chief Executive Officer & Chairman 000 0000
Patrick Schwarz-Schuette Black Pearl Investments Board Member 000 0000
Robert Weisskoff Ph.D F-Prime Capital Board Member 000 0000
Timothy Keane Golden Angels Investors Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Promentis Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Promentis Pharmaceuticals Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Aisling Capital Venture Capital Minority 000 0000 000000 0
F-Prime Capital Venture Capital Minority 000 0000 000000 0
OrbiMed PE/Buyout Minority 000 0000 000000 0
Eight Roads Venture Capital Minority 000 0000 000000 0
Michael J. Fox Foundation Limited Partner 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »